Brofobec (Beclometasone / Formoterol)
Combination inhalation spray for asthma and COPD maintenance therapy
Quick Facts About Brofobec
Key Takeaways About Brofobec
- Dual-action inhaler: Brofobec combines an anti-inflammatory corticosteroid (beclometasone) with a long-acting bronchodilator (formoterol) in a single device for convenient twice-daily maintenance therapy
- Not a rescue inhaler: Brofobec is designed for regular maintenance use and should not replace a short-acting reliever inhaler (such as salbutamol) for acute symptoms
- Rinse your mouth after use: Always rinse your mouth with water after each inhalation to prevent oral thrush (candidiasis), a common side effect of inhaled corticosteroids
- Extrafine particle formulation: The solution-based spray delivers extrafine particles that reach both large and small airways for improved drug deposition
- Regular use is essential: Brofobec works best when used consistently every day, even when you feel well, to keep airway inflammation under control
What Is Brofobec and What Is It Used For?
Brofobec is a pressurized inhalation spray containing two active substances: beclometasone dipropionate (100 micrograms) and formoterol fumarate dihydrate (6 micrograms) per actuation. It is used for the regular maintenance treatment of asthma in adults who are not adequately controlled with inhaled corticosteroids alone, and for the symptomatic treatment of severe COPD.
Brofobec belongs to the group of combination inhalers that deliver both an inhaled corticosteroid (ICS) and a long-acting beta-2 agonist (LABA) simultaneously. This combination approach is recommended by major international guidelines, including the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD), as a cornerstone of therapy for patients with persistent asthma or severe COPD.
The corticosteroid component, beclometasone dipropionate, works by reducing inflammation in the airways. Chronic inflammation is the underlying process that causes the swelling, excess mucus production, and narrowing of the airways seen in both asthma and COPD. By suppressing this inflammatory cascade, beclometasone helps prevent symptoms such as wheezing, breathlessness, and chest tightness from developing.
The second active ingredient, formoterol fumarate, is a selective long-acting beta-2 adrenergic agonist. It works by relaxing the smooth muscle that surrounds the airways, causing them to dilate and allowing air to flow more freely. Unlike short-acting bronchodilators, formoterol provides sustained bronchodilation lasting approximately 12 hours, making it suitable for twice-daily dosing. Notably, formoterol also has a relatively fast onset of action (within 1 to 3 minutes), which distinguishes it from some other long-acting bronchodilators.
Brofobec uses an extrafine particle formulation delivered as a solution aerosol. This technology produces smaller drug particles (mass median aerodynamic diameter around 1.5 micrometers) compared to conventional suspension inhalers. The advantage of extrafine particles is that they can penetrate deeper into the lungs, reaching the smaller peripheral airways where significant inflammation and airflow obstruction occur. Clinical studies have demonstrated that extrafine formulations can achieve comparable or superior clinical outcomes at lower nominal doses of corticosteroid compared to larger-particle formulations.
Indications
Brofobec is indicated for:
- Asthma: Regular maintenance treatment in adult patients not adequately controlled with inhaled corticosteroids and short-acting beta-2 agonists used as needed, or patients already adequately controlled on both an inhaled corticosteroid and a long-acting beta-2 agonist
- COPD: Symptomatic treatment of patients with severe COPD (FEV1 less than 50% of predicted normal value) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators
Brofobec is not intended for the relief of acute asthma attacks or sudden COPD exacerbations. Patients should always carry a separate short-acting rescue inhaler (such as salbutamol) for quick relief of breakthrough symptoms. If you find yourself needing your rescue inhaler more frequently, contact your healthcare provider as this may indicate worsening disease control.
What Should You Know Before Taking Brofobec?
Before starting Brofobec, inform your doctor about all medical conditions, especially heart problems, diabetes, thyroid disorders, and infections. Brofobec should not be used if you are allergic to beclometasone, formoterol, or any of the excipients. It requires careful consideration during pregnancy and breastfeeding.
Contraindications
Brofobec should not be used if you have a known hypersensitivity to beclometasone dipropionate, formoterol fumarate dihydrate, or any of the excipients in the product. While there are no absolute disease-related contraindications beyond hypersensitivity, there are several conditions that require particular caution and close medical supervision.
It is important to understand that Brofobec, like all ICS/LABA combination products, should not be initiated as the first-line therapy for newly diagnosed asthma. Current guidelines recommend that patients should first try an inhaled corticosteroid alone, and combination therapy should be considered only if symptoms remain inadequately controlled despite optimal ICS use and proper inhaler technique.
Warnings and Precautions
Special caution is needed and your doctor may wish to monitor you more closely if you have any of the following conditions:
- Cardiovascular disorders: Including coronary artery disease, cardiac arrhythmias (particularly atrioventricular block of third degree and tachyarrhythmias), hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe heart failure, severe arterial hypertension, and aneurysm
- QTc interval prolongation: Formoterol may cause prolongation of the QTc interval on ECG. Caution is advised in patients with known or suspected prolongation of the QTc interval
- Thyroid disorders: Particularly thyrotoxicosis, as beta-2 agonists may exacerbate symptoms
- Diabetes mellitus: Formoterol may cause hyperglycemia, and blood glucose monitoring may need to be intensified
- Phaeochromocytoma: Beta-2 agonists can precipitate a hypertensive crisis in patients with this condition
- Hypokalemia: Beta-2 agonists can cause a decrease in serum potassium levels. This is particularly important in patients with severe asthma where the effect may be potentiated by concomitant treatment with xanthine derivatives, corticosteroids, and diuretics
- Active or quiescent tuberculosis, fungal or viral infections of the airways: Inhaled corticosteroids may suppress the immune response in the lungs
Treatment should not be stopped abruptly without medical guidance. Sudden discontinuation of inhaled corticosteroids may trigger an asthma exacerbation or, in rare cases, adrenal insufficiency. If your doctor decides to reduce or stop your Brofobec treatment, the dose should be tapered gradually while alternative therapy is introduced.
Pregnancy and Breastfeeding
There are limited clinical data on the use of Brofobec during pregnancy. Animal studies with formoterol have shown reproductive toxicity at very high systemic exposures. However, it is well established that poorly controlled asthma during pregnancy poses significant risks to both the mother and the developing baby, including pre-eclampsia, gestational diabetes, preterm birth, and low birth weight.
Current guidelines from GINA and the British Thoracic Society (BTS) emphasize that maintaining good asthma control during pregnancy is essential, and the risks of uncontrolled asthma generally outweigh any potential risks from properly dosed inhaled medications. Beclometasone is one of the inhaled corticosteroids with the longest track record of use in pregnancy, and available evidence does not suggest an increased risk of congenital malformations.
It is expected that beclometasone dipropionate and its metabolites, as well as formoterol, are excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother. In practice, many guidelines consider low-to-moderate dose inhaled corticosteroids compatible with breastfeeding.
If you are pregnant, planning to become pregnant, or breastfeeding, discuss the benefits and risks with your healthcare provider before starting or continuing Brofobec.
How Does Brofobec Interact with Other Drugs?
Brofobec can interact with several classes of medications, including beta-blockers, QT-prolonging drugs, potassium-lowering agents, and potent CYP3A4 inhibitors. Non-selective beta-blockers should generally be avoided. Always inform your doctor and pharmacist about all medications you are taking.
Drug interactions with Brofobec arise primarily from its two active components. The formoterol component, as a beta-2 agonist, has the potential for cardiovascular and metabolic interactions, while the beclometasone component may have increased systemic exposure when combined with certain enzyme inhibitors. Understanding these interactions is crucial for safe and effective therapy.
| Interacting Drug | Severity | Effect | Recommendation |
|---|---|---|---|
| Non-selective beta-blockers (propranolol, carvedilol) | Major | Can block the bronchodilating effect of formoterol and may precipitate severe bronchospasm in asthma patients | Avoid concurrent use. If a beta-blocker is essential, use a cardioselective agent (e.g., bisoprolol) under close supervision |
| QT-prolonging drugs (sotalol, amiodarone, erythromycin, certain antipsychotics) | Major | Additive QTc prolongation, increasing risk of ventricular arrhythmias including torsades de pointes | Use with caution. ECG monitoring may be warranted. Discuss with cardiologist if combination is unavoidable |
| Potassium-lowering diuretics (furosemide, hydrochlorothiazide) | Moderate | Additive hypokalemia risk. Both beta-2 agonists and diuretics can lower serum potassium | Monitor serum potassium, especially during exacerbations and high-dose treatment periods |
| CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, cobicistat) | Moderate | May increase systemic exposure to beclometasone active metabolite (B17MP), raising the risk of systemic corticosteroid side effects including adrenal suppression | Avoid prolonged concurrent use. If necessary, consider dose adjustment and monitor for corticosteroid side effects |
| MAO inhibitors and tricyclic antidepressants | Moderate | May potentiate the cardiovascular effects of formoterol (increased heart rate, blood pressure changes) | Use with caution. Monitor cardiovascular parameters |
| Xanthine derivatives (theophylline) | Moderate | Additive hypokalemia risk and potential for increased cardiac stimulation | Monitor serum potassium and heart rate. Adjust theophylline dose if needed |
| Other sympathomimetic agents | Minor | Additive effects on heart rate and blood pressure when used concurrently with other beta-agonists or sympathomimetics | Generally acceptable for short-acting rescue inhaler use. Avoid concurrent regular LABA therapy |
Major Interactions
The most clinically significant interaction is with non-selective beta-blockers. These medications can completely negate the bronchodilating effect of formoterol and may paradoxically trigger severe bronchospasm in patients with asthma. This interaction is considered a relative contraindication. If beta-blocker therapy is medically necessary (for example, after a myocardial infarction), a cardioselective beta-blocker such as bisoprolol should be chosen and used under close medical supervision with careful monitoring of lung function.
The interaction with QT-prolonging drugs also warrants significant attention. Formoterol can cause a dose-dependent prolongation of the QTc interval on electrocardiography. When combined with other medications that share this property, the risk of potentially life-threatening ventricular arrhythmias may be increased. Patients should inform their doctor about all cardiac medications they take.
Minor Interactions
Concurrent use with other sympathomimetic agents, including over-the-counter decongestants containing pseudoephedrine, may result in additive cardiovascular effects. While the interaction with short-acting rescue inhalers (such as salbutamol) used as needed is generally considered safe and appropriate, patients should avoid using two long-acting beta-2 agonists simultaneously, as this increases the risk of adverse effects without proportional therapeutic benefit.
What Is the Correct Dosage of Brofobec?
The typical dosage of Brofobec for adults is 1 to 2 inhalations twice daily for asthma, and 2 inhalations twice daily for COPD. Your doctor will prescribe the appropriate dose based on your condition severity. Never exceed the prescribed number of puffs.
Brofobec dosing should be individualized and tailored to the severity of the disease. The goal is to achieve optimal symptom control using the lowest effective dose. Once good control is maintained for a prolonged period, your doctor may consider a stepwise dose reduction. The medication should be used regularly every day, even during periods when you feel well, to maintain control of airway inflammation.
Adults
Asthma - Maintenance Therapy
Standard dose: 1 to 2 inhalations twice daily
Maximum dose: 2 inhalations twice daily (total daily dose: 400 mcg beclometasone / 24 mcg formoterol)
Patients should be reviewed regularly to ensure the prescribed dose remains appropriate. Dose adjustments should only be made on medical advice.
COPD - Maintenance Therapy
Recommended dose: 2 inhalations twice daily
Maximum dose: 2 inhalations twice daily
Clinical benefit in COPD has been demonstrated with treatment durations of up to 48 weeks in clinical trials.
Children and Adolescents
Brofobec 100/6 mcg is generally not recommended for children and adolescents under 18 years of age. There is insufficient clinical data to support its use in this age group. Alternative ICS/LABA combinations with pediatric dosing data and specific formulations for children should be considered. Your child's doctor will advise on the most appropriate treatment.
Elderly Patients
No dose adjustment is required in elderly patients. However, as with all inhaled medications, attention should be paid to ensuring correct inhaler technique, which can be more challenging for older adults. Elderly patients may also be more susceptible to certain side effects, particularly hypokalemia and cardiovascular effects of formoterol, and may require more frequent monitoring.
Missed Dose
If you forget to take a dose of Brofobec, take it as soon as you remember. However, if it is almost time for your next scheduled dose, simply skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the one you missed. Setting a regular time for your doses (for example, morning and evening) can help you remember to use your inhaler consistently.
Overdose
Overdose with formoterol may produce symptoms typical of excessive beta-2 adrenergic stimulation, including tremor, headache, palpitations, tachycardia, nausea, hyperglycemia, and hypokalemia. In severe cases, metabolic acidosis and cardiac arrhythmias may occur. Treatment is supportive and symptomatic. Cardioselective beta-blockers may be considered in severe cases, but should be used with extreme caution in patients with a history of bronchospasm.
Chronic overdosage of the beclometasone component may lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis. If higher doses than recommended are used over prolonged periods, clinically significant adrenal suppression may occur. In cases of suspected adrenal suppression, monitoring of adrenal reserve and temporary supplementation with systemic corticosteroids may be necessary.
If you suspect an overdose of Brofobec, contact your local poison control center or emergency department immediately. Bring the inhaler with you so healthcare professionals can see exactly what was taken.
| Indication | Patient Group | Dose | Frequency |
|---|---|---|---|
| Asthma (maintenance) | Adults (18+) | 1-2 inhalations | Twice daily |
| Asthma (max dose) | Adults (18+) | 2 inhalations | Twice daily |
| COPD (maintenance) | Adults (18+) | 2 inhalations | Twice daily |
| Asthma / COPD | Children (<18) | Not recommended | N/A |
| Asthma / COPD | Elderly | No dose adjustment | As per adults |
What Are the Side Effects of Brofobec?
Like all medicines, Brofobec can cause side effects, although not everyone experiences them. The most common side effects are oral thrush, hoarseness, sore throat, headache, and tremor. Serious side effects such as paradoxical bronchospasm and allergic reactions are rare but require immediate medical attention.
The side effects of Brofobec reflect those associated with its individual components. Inhaled corticosteroids are generally well tolerated when used at recommended doses, as they act primarily locally in the airways with minimal systemic absorption. However, some local effects in the mouth and throat are relatively common. The beta-2 agonist component can cause systemic effects related to adrenergic stimulation, although these are typically mild and tend to diminish with continued use.
It is important to put side effects in perspective. For most patients, the benefits of well-controlled asthma or COPD far outweigh the risks of side effects from inhaled medication. Uncontrolled airway disease carries its own significant risks, including frequent exacerbations, hospitalizations, permanent airway remodeling, and in severe cases, life-threatening attacks.
Very Common (more than 1 in 10 patients)
- Oral candidiasis (thrush) - white patches in mouth and throat
Common (1 in 10 to 1 in 100 patients)
- Dysphonia (hoarseness or voice changes)
- Pharyngitis (sore throat) and throat irritation
- Headache
- Tremor (fine shaking, especially of the hands)
- Palpitations (awareness of heartbeat)
- Influenza-like symptoms
- Nasopharyngitis (common cold symptoms)
Uncommon (1 in 100 to 1 in 1,000 patients)
- Tachycardia (rapid heartbeat)
- Muscle cramps and myalgia
- Dizziness
- Agitation, restlessness, nervousness
- Nausea
- Skin rash, pruritus (itching), urticaria (hives)
- Hyperglycemia (elevated blood sugar)
- Hypokalemia (low potassium levels)
- Prolongation of QTc interval on ECG
Rare (less than 1 in 1,000 patients)
- Paradoxical bronchospasm (worsening of breathing immediately after inhalation)
- Angioedema (swelling of face, lips, tongue, or throat)
- Adrenal suppression (with prolonged high-dose use)
- Growth retardation in children (with prolonged use)
- Glaucoma and cataracts (with prolonged high-dose use)
- Decreased bone mineral density (with prolonged high-dose use)
- Sleep disturbances and behavioral changes (insomnia, anxiety, depression)
- Cardiac arrhythmias (atrial fibrillation, ventricular extrasystoles)
Paradoxical bronchospasm (sudden worsening of wheezing and shortness of breath immediately after using the inhaler), signs of a severe allergic reaction (difficulty breathing, swelling of face/lips/tongue, severe rash), chest pain, or irregular heartbeat. These are rare but serious side effects that require urgent medical evaluation.
How to Minimize Side Effects
Several practical measures can help reduce the risk and severity of side effects from Brofobec:
- Rinse your mouth: After every inhalation, rinse your mouth thoroughly with water and spit it out. This removes residual corticosteroid from the oral cavity and significantly reduces the risk of oral candidiasis and hoarseness
- Use correct technique: Proper inhaler technique ensures maximum drug delivery to the lungs and minimizes deposition in the mouth and throat. Ask your pharmacist or nurse to demonstrate and check your technique regularly
- Use the lowest effective dose: Work with your doctor to find the minimum dose of Brofobec that maintains good symptom control
- Report persistent side effects: If you experience troublesome side effects, discuss them with your doctor rather than stopping the medication on your own
How Should You Use Brofobec Inhaler?
Shake the Brofobec inhaler well before each use. Breathe out gently, place the mouthpiece between your lips, inhale slowly and deeply while pressing the canister, and hold your breath for about 10 seconds. Rinse your mouth with water afterward. Use the inhaler at the same times each day for best results.
Correct inhaler technique is essential for effective drug delivery to the lungs. Studies have consistently shown that a significant proportion of patients use their pressurized metered-dose inhalers (pMDIs) incorrectly, which can lead to poor symptom control and unnecessary dose escalation. Taking time to learn and regularly review proper technique can substantially improve treatment outcomes.
Step-by-Step Instructions
- Prepare the inhaler: Remove the protective cap from the mouthpiece. If the inhaler is new or has not been used for 14 days or more, release one test spray into the air away from your face
- Shake well: Shake the inhaler vigorously for 5 seconds to ensure the medication is evenly mixed
- Breathe out: Hold the inhaler upright. Breathe out slowly and completely through your mouth (not through the inhaler)
- Inhale: Place the mouthpiece between your lips and close your lips firmly around it. Begin to breathe in slowly and deeply through your mouth, and at the same time press the top of the canister down firmly to release one puff
- Hold your breath: Remove the inhaler from your mouth and hold your breath for approximately 10 seconds, or as long as is comfortable
- Wait: If a second inhalation is required, wait at least 30 seconds before repeating steps 2 through 5
- Replace the cap: Replace the protective mouthpiece cap after use
- Rinse your mouth: Rinse your mouth with water and spit it out to reduce the risk of oral thrush and hoarseness
If you find it difficult to coordinate pressing the canister and breathing in at the same time, ask your doctor or pharmacist about using a spacer (valved holding chamber) with your Brofobec inhaler. A spacer can improve drug delivery to the lungs and reduce oral deposition, making the inhaler easier to use effectively.
How Should You Store Brofobec?
Store Brofobec below 25°C (77°F). Do not freeze. Protect from direct sunlight and heat. The pressurized canister should not be punctured, broken, or burned, even when apparently empty.
Proper storage is important to ensure that Brofobec remains effective throughout its shelf life. Like all pressurized metered-dose inhalers, Brofobec contains a propellant under pressure and must be stored and handled with appropriate care.
- Temperature: Store at temperatures below 25°C (77°F). Do not expose to temperatures higher than 50°C (122°F)
- Do not freeze: Freezing may affect the performance of the valve and the uniformity of the spray
- Protect from sunlight: Keep the inhaler away from direct sunlight and other heat sources
- Pressurized container: Do not puncture, break, or burn the canister, even when it appears empty
- Keep out of reach of children: Store in a safe location inaccessible to children
- Clean regularly: Clean the mouthpiece at least once a week. Remove the canister and rinse the plastic actuator and cap with warm water. Allow to air dry completely before reassembling
Do not use Brofobec after the expiry date printed on the canister and outer carton. The expiry date refers to the last day of the indicated month. Once the labeled number of actuations have been used, the inhaler should be discarded even if some liquid appears to remain in the canister, as the remaining actuations may not deliver the correct dose.
What Does Brofobec Contain?
Each actuation of Brofobec delivers 100 micrograms of beclometasone dipropionate and 6 micrograms of formoterol fumarate dihydrate. The solution also contains excipients including ethanol, hydrochloric acid, and the propellant norflurane (HFA-134a).
Active Ingredients
- Beclometasone dipropionate: 100 micrograms per actuation. A synthetic glucocorticoid with potent anti-inflammatory properties. In the extrafine formulation, it reaches both central and peripheral airways
- Formoterol fumarate dihydrate: 6 micrograms per actuation. A selective long-acting beta-2 adrenergic agonist providing bronchodilation for approximately 12 hours with a rapid onset of action
Excipients (Inactive Ingredients)
- Norflurane (HFA-134a): The propellant used to deliver the medication as a fine spray. This is a non-CFC propellant, in line with the Montreal Protocol
- Ethanol, anhydrous: Used as a co-solvent to dissolve the active ingredients in the solution formulation
- Hydrochloric acid: A pH adjuster to maintain stability of the formulation
Brofobec delivers the active ingredients in an extrafine particle size (mass median aerodynamic diameter approximately 1.5 micrometers). This means the drug particles are smaller than in conventional inhalers, allowing them to reach the smaller peripheral airways. The extrafine formulation achieves effective lung deposition of approximately 30-34% of the metered dose, which is higher than many conventional suspension-based inhalers.
Frequently Asked Questions About Brofobec
Brofobec is a maintenance (controller) inhaler designed for regular daily use to prevent symptoms and control underlying airway inflammation. A rescue inhaler (such as salbutamol or terbutaline) is a short-acting bronchodilator used on-demand for quick relief of acute symptoms. You should continue to carry your rescue inhaler alongside Brofobec. While formoterol in Brofobec does have a fast onset, the inhaler should primarily be used on its regular schedule as directed by your doctor.
The formoterol component of Brofobec starts to produce bronchodilation within 1 to 3 minutes, providing relatively quick symptom relief. However, the full anti-inflammatory effect of the beclometasone component takes longer to develop. You may notice progressive improvement in your symptoms over the first few days to weeks of regular use. Maximum benefit from the corticosteroid component is typically achieved after 1 to 2 weeks of consistent, twice-daily use. It is crucial to continue using Brofobec regularly even if you feel well.
There is no direct interaction between Brofobec and alcohol. Moderate alcohol consumption is generally acceptable. However, be aware that alcohol can trigger asthma symptoms in some individuals, particularly those with sensitivity to sulfites found in wine and beer. Additionally, alcohol can interact with other medications you may be taking for your respiratory condition or other health issues. Discuss your individual situation with your doctor.
If your symptoms worsen, increase in frequency, or if you need to use your rescue inhaler more often than usual, this may indicate that your asthma is not well controlled. Do not increase the dose of Brofobec without medical advice. Contact your doctor promptly, as your treatment plan may need adjustment. If you experience a sudden, severe worsening of symptoms (an asthma attack), use your rescue inhaler immediately and seek emergency medical care if symptoms do not improve quickly.
Brofobec inhalers contain a specified number of actuations (usually indicated on the canister label). You can track your usage by counting doses or noting the start date and calculating when you will have used the labeled number of puffs. Some inhalers have a dose counter built in. Do not rely on shaking the canister or floating it in water, as these methods are unreliable. Order a refill prescription before your current inhaler runs out to avoid gaps in treatment.
Brofobec, Foster, and Innovair all contain the same combination of active ingredients (beclometasone dipropionate and formoterol fumarate) in an extrafine particle formulation. They are essentially the same medication sold under different brand names in different markets. Brofobec may be a generic or parallel-imported version. While the active ingredients and their doses are the same, minor differences in excipients or device design may exist. Always use the specific product prescribed by your doctor and discuss any brand switches with your pharmacist.
References
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2024. Available at: ginasthma.org
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD, 2024. Available at: goldcopd.org
- European Medicines Agency (EMA). Summary of Product Characteristics for beclometasone/formoterol fixed combination inhalers. ema.europa.eu
- British National Formulary (BNF). Beclometasone with formoterol. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Papi A, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. The Lancet. 2018;391(10125):1076-1084.
- Singh D, et al. Extrafine beclometasone dipropionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease. NPJ Primary Care Respiratory Medicine. 2016;26:16030.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List, 2023. Available at: who.int
- British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN). British guideline on the management of asthma, 2024.
- Usmani OS, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respiratory Research. 2018;19:10.
- Lavorini F, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respiratory Medicine. 2008;102(4):593-604.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specialization in respiratory medicine and clinical pharmacology. Our team follows international evidence-based guidelines including GINA, GOLD, BTS/SIGN, and EMA recommendations.
Medical Review Process
- Written by medical professionals
- Peer-reviewed by specialist physicians
- Based on international guidelines (GINA, GOLD, EMA)
- Updated regularly to reflect current evidence
Quality Standards
- Evidence Level 1A methodology
- GRADE evidence framework
- No commercial funding or conflicts of interest
- WCAG 2.2 AAA accessible content